Compare PW & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PW | BDRX |
|---|---|---|
| Founded | 1967 | 2000 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 2.4M |
| IPO Year | N/A | N/A |
| Metric | PW | BDRX |
|---|---|---|
| Price | $0.93 | $4.91 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 42.7K |
| Earning Date | 10-24-2025 | 09-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,075,489.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.59 | $3.58 |
| 52 Week High | $2.59 | $92.00 |
| Indicator | PW | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.57 | 47.66 |
| Support Level | $0.75 | $3.60 |
| Resistance Level | $1.04 | $4.80 |
| Average True Range (ATR) | 0.12 | 0.53 |
| MACD | 0.04 | 0.11 |
| Stochastic Oscillator | 63.11 | 66.20 |
Power REIT is an internally managed real estate investment trust (REIT) that owns a portfolio of real estate assets related to transportation, energy infrastructure, and Controlled Environment Agriculture (CEA) in the United States. Its investment portfolio comprises solar farm lands, railroad real estate, and various Controlled Environment Agriculture properties in the form of greenhouses for the cultivation of food and cannabis. In addition, the company is focused on opportunities in the form of investing in distressed situations, including debt and other types of secured interests in real estate, distressed properties, and real estate-related companies.
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.